Intellia Therapeutics Inc (NASDAQ:NTLA) saw unusually-strong trading volume on Thursday . Approximately 566,977 shares traded hands during trading, an increase of 181% from the previous session’s volume of 201,584 shares.The stock last traded at $18.95 and had previously closed at $18.45.

Several research analysts recently weighed in on NTLA shares. Leerink Swann started coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They set a “market perform” rating and a $32.00 target price on the stock. Credit Suisse Group AG initiated coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They set an “outperform” rating and a $39.00 price target for the company. Wedbush initiated coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They set an “outperform” rating and a $38.00 price target for the company. Finally, Jefferies Group initiated coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They set a “hold” rating and a $33.00 price target for the company.

The stock’s market capitalization is $682.12 million. The company has a 50 day moving average price of $22.04 and a 200 day moving average price of $24.05.

In related news, major shareholder Institutes For Biomed Novartis acquired 277,777 shares of Intellia Therapeutics stock in a transaction dated Wednesday, May 11th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $4,999,986.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Carl L. Gordon acquired 250,000 shares of Intellia Therapeutics stock in a transaction dated Wednesday, May 11th. The stock was bought at an average price of $18.00 per share, for a total transaction of $4,500,000.00. The disclosure for this purchase can be found here.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.